Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Re-treatment with direct acting antivirals for chronic hepatitis C genotype 1: emerging evidence of clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions No relevant conference abstracts were identified regarding the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy. Indexing Status Subject indexing assigned by CRD MeSH Antiviral Agentss; Hepatitis C, Chronic; Recurrence Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000752 Date abstract record published 08/07/2014 |